Streetbeat News

Price Targets

ETNB

RBC Capital analyst Brian Abrahams maintains an 'Outperform' rating on 89bio (NASDAQ:ETNB) and raises the price target from $33 to $34.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:12 pm

BERY

Wells Fargo analyst Gabe Hajde has maintained an Overweight rating on Berry Global Gr (NYSE:BERY) but lowered the price target from $78 to $74.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 2:11 pm

TSX:WSP

RBC Capital analyst Sabahat Khan maintains an 'Outperform' rating on WSP Global and raises the price target from C$199 to C$210.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:09 pm

TSX:FORA

RBC Capital analyst Drew McReynolds maintains an Outperform rating on VerticalScope Holdings and raises the price target from C$11 to C$12.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:08 pm

SGMO

Wells Fargo analyst Yanan Zhu has maintained an Overweight rating on Sangamo Therapeutics (NASDAQ:SGMO) but lowered the price target from $5 to $4.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 2:08 pm

SLF

RBC Capital analyst Darko Mihelic has maintained an 'Outperform' rating on Sun Life Financial (TSX:SLF) but lowered the price target from C$79 to C$76.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:07 pm

TSX:SJ

RBC Capital analyst Walter Spracklin has maintained an Outperform rating on Stella-Jones and raised the price target from C$69 to C$79.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:06 pm

ZNTL

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Zentalis Pharma (NASDAQ:ZNTL) but lowered the price target from $51 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 2:05 pm

TSX:QFOR

RBC Capital analyst Maxim Matushansky maintains a 'Sector Perform' rating on Q4 (TSX:QFOR) and raises the price target from C$3.25 to C$3.75.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:05 pm

NVEI

RBC Capital analyst Paul Treiber has maintained an 'Outperform' rating on Nuvei (NASDAQ:NVEI), but lowered the price target from $42 to $29.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 2:04 pm